Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized Comparison of Femara 2.5mg Once Daily With or Without Weekly Herceptin Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer.

Next Previous
Trial Profile

An Open Label, Randomized Comparison of Femara 2.5mg Once Daily With or Without Weekly Herceptin Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms eLEcTRA

    • Most Recent Events

    • 12 Dec 2009 Actual number of patients changed from 93 to 92 according to an abstract from the 32nd Annual San Antonio Breast Cancer Symposium.
    • 12 Dec 2009 Results presented at the 32nd Annual San Antonio Breast Cancer Symposium.
    • 11 Aug 2009 Actual patient number (93) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top